Navigation Links
Study of Mechanism of Action of Ibrutinib in Mantle Cell Lymphoma Published in Blood - Journal of the American Society of Hematology
Date:8/22/2013

development-and-worldwide-license-agreement-for-investigational-anti-cancer-drug-pci-32765">December 2011 to co-develop and co-commercialize ibrutinib.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

Pharmacyclics is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our futu
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
2. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
3. Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update
4. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
5. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
6. Astellas Confirms Interim Analysis in PREVAIL Study of XTANDI will Occur within Calendar Year 2013
7. Physicians Expect More Out of Tablet-Toting Pharmaceutical Sales Reps, Study Finds
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
10. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
11. Recent Study Reveals Physicians Prefer Topical Delivery for Drug Delivery Technology, Such as a Transdermal Patch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... South Africa , Jan. 23, 2015   Leatt ... of personal protective equipment for all forms of sports, ... flagship Leatt-Brace® neck brace, announced today that the UISP ... federation, now requires all riders to wear a neck ...
(Date:1/23/2015)... China , Jan. 23, 2015 Tianyin Pharmaceutical ... company that specializes in the development and sale of ... generics and active pharmaceutical ingredients (API) today announced the ... (JCM) API operation. 1. Following the September ...
(Date:1/22/2015)... 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or ... Omega-3 therapies for cardiovascular disease and overall health is pleased ... in 2014 and its outlook for 2015 from the CEO, ... We would like to take this opportunity to ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Sandwich" Device is First to Mimic Natural Physical Environment, ... challenges to islet,cell transplantation as the treatment of choice ... supply. Patients often need a re-infusion of islet,cells after ... is,needed to provide the fragile islet cells for transplant. ...
... In Patients With BPH, Clinical Benefit After Ozarelix Was Maintained For ... ... Commence Before Year End Or Soon Thereafter, IRVINE, Calif., Sept. 5 ... and efficacy data for ozarelix, the Company,s drug candidate for the,treatment of ...
Cached Medicine Technology:Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells 2Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 2Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 3Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 4Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 5
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... JOSE, Calif., May 22 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... the minimally invasive treatment of venous reflux disease, today,announced ... 12th Annual,Spring Investor Conference, to be held May 28-29, ... NY., VNUS, presentation is currently scheduled for 12:50 ...
... DURHAM, N.C. -- A new study by Duke University researchers provides ... of a cell plays a key role in disease, and the ... heart disease and cancer. , The nitric oxide system in cells ... regard to the way it controls proteins, and it is linked ...
... HHS Secretary Mike,Leavitt today announced efforts underway ... the Centers for Medicare & Medicaid Services (CMS),that ... and the quality,of medical care., "This initiative ... use of medical products on the market," Secretary ...
... study suggests threat of starvation triggers the switch , , ... suggests the body,s biological clock, which regulates sleep cycles ... can be overridden in extreme situations by an internal ... with mice and has not yet been tested among ...
... For patients undergoing kidney transplantation, treatment with the anti-rejection ... diabetes, reports a study in the July Journal of ... a robust association between sirolimus and diabetes after transplantation ... the United States," comments Dr. John S. Gill of ...
... (Amex:,ADL), ( http://www.amdl.com ), a world leader ... Jilin, China, announced today that,it has made available ... financial results conference call. The document can be ... Click on "Investor Relations",then "Recent News.", The ...
Cached Medicine News:Health News:Major 'missed' biochemical pathway emerges as important in virtually all cells 2Health News:Major 'missed' biochemical pathway emerges as important in virtually all cells 3Health News:New Efforts to Help Improve Medical Products for Patient Safety and Quality of Medical Care 2Health News:New Efforts to Help Improve Medical Products for Patient Safety and Quality of Medical Care 3Health News:New Efforts to Help Improve Medical Products for Patient Safety and Quality of Medical Care 4Health News:'Food Clock' May Override Master Sleep Clock in Times of Duress 2Health News:'Food Clock' May Override Master Sleep Clock in Times of Duress 3Health News:'Food Clock' May Override Master Sleep Clock in Times of Duress 4Health News:Anti-rejection drug may increase risk of diabetes after kidney transplant 2Health News:AMDL Teleconference Available on amdl.com at 5:00 p.m. EDT Today 2
... an average 5:1 increase in usage time at ... a standard cannula. , ,The combination of ... oxygen patients a superior alternative to liquid oxygen. ... , ,NOTE: Each ...
... An All-In-One Conserver., ,Offers an average 5:1 ... ,Allows the use of a standard cannula. ... and lightweight cylinders offers ambulatory oxygen patients a ... backed by a 2-year warranty. ...
Redesigning the World's Oxygen Therapy One Device at a Time. , ,Everything you like about our OXYMATIC 400 Series conservers, only better!...
... Conservation Device. Bypass 6200: Direct ... Accessories: , OCD870C CGA 870 ... Regulator , OCD2001-18 Carrying Pouch ... CP2140 Vertical M-6 Cylinder Carrying ...
Medicine Products: